A recent ruling by the US Court of Appeals for the Second Circuit has reignited legal proceedings against Kenvue, the manufacturer of Tylenol, by reversing a previous dismissal of lawsuits. The original dismissal, issued by a trial judge, had halted hundreds of cases filed by families who alleged a link between maternal use of Tylenol during pregnancy and the development of autism or attention deficit hyperactivity disorder (ADHD) in children. The appellate decision highlighted the district court’s overreach in excluding certain expert testimonies and underscored the need to consider new studies published on this matter.
The litigation, initially launched in 2022, hinges on claims that acetaminophen, the active ingredient in Tylenol, could contribute to developmental disorders in children when ingested by pregnant women. In response to growing concern, the White House, in September 2025, issued an official statement via Press Secretary Karoline Leavitt. The administration advised caution in using Tylenol during pregnancy, citing emerging evidence of a potential connection with autism. President Trump also expressed skepticism about acetaminophen, advocating for avoiding the drug during pregnancy.
Despite these legal and political developments, medical authorities, including the American College of Obstetricians and Gynecologists (ACOG) and the American Academy of Pediatrics (AAP), have maintained their stance on the safety of Tylenol when used correctly during pregnancy. These organizations emphasize the absence of definitive scientific evidence linking acetaminophen to autism or ADHD. Reuters reported the case is set to return to Judge Denise Cote in the Southern District of New York, where it will be heard anew with the potential incorporation of recent scientific findings.
This development underscores the evolving landscape of pharmaceutical litigation, where emerging research and policy statements can significantly impact ongoing legal battles. As the case progresses, it will likely continue to attract attention from both legal experts and public health authorities, given the potential implications for consumers and drug manufacturers alike.